Drug updated on 10/30/2024
Dosage Form | Injection (intravenous; 600 mg/6 mL [100 mg/mL]) |
Drug Class | Monoclonal antibodies against B. anthracis |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in adult and pediatric patients for treatment of inhalational anthrax due to B
- anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Effectiveness in Animal Models: Obiltoxaximab increased survival rates after anthrax exposure in New Zealand White Rabbits and Cynomolgus Macaques, demonstrating effectiveness in these specific animal models.
- Lack of Comparative Data: The reviewed studies did not include data comparing the effectiveness of obiltoxaximab with other treatments, so no comparative conclusions can be drawn.
- Safety in Human Studies: Obiltoxaximab was well-tolerated in healthy human volunteers, with a relatively low incidence of adverse events reported.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Anthim (obiltoxaximab) Prescribing Information. | 2023 | Elusys Therapeutics, Inc., Parsippany, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection | 2017 | The Annals of pharmacotherapy |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Virginia Department of Health Anthrax: Guidance for Healthcare Providers Key Medical and Public Health Interventions after Identification of a Suspected Case. | 2023 | Virginia Department of Health |
CDC Guidelines for the Prevention and Treatment of Anthrax, 2023 | 2023 | Morbidity and Mortality Weekly Report- Recommendations and Reports |
Use of anthrax vaccine in the United States: Recommendations of the advisory committee on immunization practices, 2019. | 2019 | Morbidity and Mortality Weekly Report- Recommendations and Reports |